Symbols / CDIO Stock $1.82 +0.00% Cardio Diagnostics Holdings, Inc.

Healthcare • Biotechnology • United States • NCM
CDIO (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Meeshanthini V. Dogan Ph.D.
Exch · Country NCM · United States
Market Cap 5.39M
Enterprise Value 971.22K
Income -6.50M
Sales 14.82K
FCF (ttm) -3.81M
Book/sh 3.82
Cash/sh 1.73
Employees 15
Insider 10d —
IPO Jan 14, 2022
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -7.28
PEG —
P/S 363.32
P/B 0.48
P/C —
EV/EBITDA -0.16
EV/Sales 65.51
Quick Ratio 8.46
Current Ratio 9.79
Debt/Eq 9.97
LT Debt/Eq —
EPS (ttm) -3.71
EPS next Y -0.25
EPS Growth —
Revenue Growth -21.20%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-14
Earnings (prior) 2025-05-15
ROA -44.09%
ROE -78.62%
ROIC —
Gross Margin 100.00%
Oper. Margin -411.60%
Profit Margin 0.00%
Shs Outstand 2.96M
Shs Float 2.83M
Insider Own 8.31%
Instit Own 4.38%
Short Float 1.82%
Short Ratio 0.27
Short Interest 53.76K
52W High 15.00
vs 52W High -87.87%
52W Low 0.97
vs 52W Low 87.63%
Beta 2.66
Impl. Vol. —
Rel Volume 0.01
Avg Volume 3.60M
Volume 28.92K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $1.82
Price $1.82
Change 0.00%
About

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers; provider organizations, such as concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$1.82
Latest analyst target
3. DCF / Fair value
$-23.17
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.82
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2024-08-27 reit Benchmark Speculative Buy → Speculative Buy $2
2024-06-06 main Benchmark Speculative Buy → Speculative Buy $2
2024-04-19 main Benchmark Speculative Buy → Speculative Buy $1
2023-06-15 reit Benchmark Speculative Buy → Speculative Buy $8
2023-05-22 init Northland Capital Markets — → Outperform $8
2023-04-18 reit Benchmark — → Speculative Buy $8
News
RSS: Latest CDIO news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2024-09-06 DOGAN MEESHANTHINI Chief Technology Officer — 68,965 $0.29 $20,000
2024-09-06 DOGAN MEESHANTHINI Chief Executive Officer — 68,965 $0.29 $20,000
2024-09-06 DOGAN MEESHANTHINI Chief Executive Officer — 68,965 $0.29 $20,000
2024-09-06 DOGAN TIMUR Chief Technology Officer — 68,965 $0.29 $20,000
2024-09-06 DOGAN TIMUR Chief Technology Officer — 68,965 $0.29 $20,000
2024-09-06 PHILIBERT ROBERT Officer and Director — 34,075 $0.28 $9,763
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.01
-57.51%
0.03
+104.45%
0.02
+1696.32%
0.00
Operating Revenue
0.01
-57.51%
0.03
+104.45%
0.02
+1696.32%
0.00
Operating Expense
6.50
-22.64%
8.40
+15.72%
7.26
+59.57%
4.55
Research And Development
0.64
+181.28%
0.23
+57.02%
0.15
+258.93%
0.04
Selling General And Administration
5.79
-28.95%
8.15
+14.91%
7.10
+57.92%
4.49
Selling And Marketing Expense
0.77
-37.75%
1.23
+677.20%
0.16
+71.00%
0.09
General And Administrative Expense
5.03
-27.39%
6.92
-0.22%
6.94
+57.64%
4.40
Other Gand A
5.03
-27.39%
6.92
-0.22%
6.94
+57.64%
4.40
Total Expenses
6.50
-22.64%
8.40
+15.72%
7.26
+59.57%
4.55
Operating Income
-6.48
+22.49%
-8.37
-15.51%
-7.24
-59.23%
-4.55
Total Operating Income As Reported
-6.48
+22.49%
-8.37
-15.51%
-7.24
-59.23%
-4.55
EBITDA
-6.09
+24.77%
-8.09
-428.59%
-1.53
+67.06%
-4.64
Normalized EBITDA
-6.09
+24.77%
-8.09
-13.45%
-7.13
-57.30%
-4.53
Reconciled Depreciation
0.40
+44.07%
0.28
+147.58%
0.11
+597.63%
0.02
EBIT
-6.48
+22.49%
-8.36
-409.48%
-1.64
+64.78%
-4.66
Total Unusual Items
—
0.00
-100.00%
5.60
+5075.89%
-0.11
Total Unusual Items Excluding Goodwill
—
0.00
-100.00%
5.60
+5075.89%
-0.11
Special Income Charges
—
0.00
-100.00%
0.19
+271.81%
-0.11
Other Special Charges
—
—
-0.19
—
Restructuring And Mergern Acquisition
—
—
0.00
-100.00%
0.11
Net Income
-6.50
+22.49%
-8.38
-0.08%
-8.38
-79.72%
-4.66
Pretax Income
-6.50
+22.49%
-8.38
-0.08%
-8.38
-79.72%
-4.66
Net Non Operating Interest Income Expense
-0.01
+19.84%
-0.02
+99.74%
-6.73
0.00
Interest Expense Non Operating
0.01
-20.60%
0.02
-99.72%
6.74
0.00
Net Interest Income
-0.01
+19.84%
-0.02
+99.74%
-6.73
0.00
Interest Expense
0.01
-20.60%
0.02
-99.72%
6.74
0.00
Interest Income Non Operating
0.00
-33.08%
0.00
-0.37%
0.00
0.00
Interest Income
0.00
-33.08%
0.00
-0.37%
0.00
0.00
Other Income Expense
—
—
5.60
+5075.89%
-0.11
Gain On Sale Of Security
—
—
5.41
—
Tax Provision
0.00
0.00
0.00
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-6.50
+22.49%
-8.38
-0.08%
-8.38
-79.72%
-4.66
Net Income From Continuing Operation Net Minority Interest
-6.50
+22.49%
-8.38
-0.08%
-8.38
-79.72%
-4.66
Net Income From Continuing And Discontinued Operation
-6.50
+22.49%
-8.38
-0.08%
-8.38
-79.72%
-4.66
Net Income Continuous Operations
-6.50
+22.49%
-8.38
-0.08%
-8.38
-79.72%
-4.66
Normalized Income
-6.50
+22.49%
-8.38
+40.02%
-13.98
-207.28%
-4.55
Net Income Common Stockholders
-6.50
+22.49%
-8.38
-0.08%
-8.38
-79.72%
-4.66
Diluted EPS
—
-9.35
+52.78%
-19.80
+56.29%
-45.30
Basic EPS
—
-9.35
+52.78%
-19.80
+56.29%
-45.30
Basic Average Shares
—
0.90
+112.00%
0.42
+310.83%
0.10
Diluted Average Shares
—
0.90
+112.00%
0.42
+310.83%
0.10
Diluted NI Availto Com Stockholders
-6.50
+22.49%
-8.38
-0.08%
-8.38
-79.72%
-4.66
Amortization
0.07
+230.49%
0.02
+2.90%
0.02
+19.89%
0.02
Amortization Of Intangibles Income Statement
0.07
+230.49%
0.02
+2.90%
0.02
+19.89%
0.02
Depreciation Amortization Depletion Income Statement
0.07
+230.49%
0.02
+2.90%
0.02
+19.89%
0.02
Depreciation And Amortization In Income Statement
0.07
+230.49%
0.02
+2.90%
0.02
+19.89%
0.02
Line Item Trend 2023-12-31
Total Assets
4.46
Current Assets
2.77
Cash Cash Equivalents And Short Term Investments
1.28
Cash And Cash Equivalents
1.28
Cash Financial
1.28
Receivables
0.00
Accounts Receivable
0.00
Prepaid Assets
—
Other Current Assets
1.48
Total Non Current Assets
1.70
Net PPE
1.15
Gross PPE
1.15
Accumulated Depreciation
-0.00
Properties
0.00
Machinery Furniture Equipment
0.09
Other Properties
0.58
Leases
0.48
Goodwill And Other Intangible Assets
0.54
Other Intangible Assets
0.54
Non Current Prepaid Assets
0.01
Total Liabilities Net Minority Interest
1.50
Current Liabilities
0.84
Payables And Accrued Expenses
0.24
Payables
0.24
Accounts Payable
0.24
Other Payable
0.37
Current Debt And Capital Lease Obligation
0.60
Current Debt
0.37
Other Current Borrowings
0.37
Current Capital Lease Obligation
0.22
Total Non Current Liabilities Net Minority Interest
0.66
Long Term Debt And Capital Lease Obligation
0.66
Long Term Capital Lease Obligation
0.66
Tradeand Other Payables Non Current
—
Other Non Current Liabilities
—
Stockholders Equity
2.96
Common Stock Equity
2.96
Capital Stock
0.00
Common Stock
0.00
Preferred Stock
0.00
Share Issued
0.68
Ordinary Shares Number
0.68
Treasury Shares Number
0.00
Additional Paid In Capital
17.33
Retained Earnings
-14.37
Total Equity Gross Minority Interest
2.96
Total Capitalization
2.96
Working Capital
1.92
Invested Capital
3.33
Total Debt
1.26
Capital Lease Obligations
0.89
Net Tangible Assets
2.42
Tangible Book Value
2.42
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-5.73
-14.69%
-4.99
+11.97%
-5.67
-11.42%
-5.09
Cash Flow From Continuing Operating Activities
-5.73
-14.69%
-4.99
+11.97%
-5.67
-11.42%
-5.09
Net Income From Continuing Operations
-6.50
+22.49%
-8.38
-0.08%
-8.38
-79.72%
-4.66
Depreciation Amortization Depletion
0.40
+44.07%
0.28
+147.58%
0.11
+597.63%
0.02
Depreciation
0.16
+40.68%
0.11
+2902.03%
0.00
0.00
Amortization Cash Flow
0.24
+46.44%
0.16
+50.76%
0.11
+573.94%
0.02
Depreciation And Amortization
0.40
+44.07%
0.28
+147.58%
0.11
+597.63%
0.02
Amortization Of Intangibles
0.24
+46.44%
0.16
+50.76%
0.11
+573.94%
0.02
Other Non Cash Items
—
—
6.70
+5857.77%
0.11
Stock Based Compensation
0.11
-95.75%
2.59
+102.55%
1.28
0.00
Operating Gains Losses
—
—
-5.60
—
Gain Loss On Investment Securities
—
—
-5.41
—
Change In Working Capital
0.26
-49.70%
0.52
+150.38%
0.21
+137.39%
-0.56
Change In Receivables
0.01
+176.81%
-0.01
-175.24%
-0.00
-650.50%
0.00
Changes In Account Receivables
0.01
+176.81%
-0.01
-175.24%
-0.00
-650.50%
0.00
Change In Prepaid Assets
0.48
-47.60%
0.92
+22.00%
0.75
+207.90%
-0.70
Change In Payables And Accrued Expense
0.01
+106.29%
-0.16
+80.10%
-0.78
-673.14%
0.14
Change In Other Current Liabilities
-0.24
-5.96%
-0.22
-191.58%
0.24
0.00
Investing Cash Flow
-0.42
-3.74%
-0.40
+49.11%
-0.79
-115.84%
-0.37
Cash Flow From Continuing Investing Activities
-0.42
-3.74%
-0.40
+49.11%
-0.79
-115.84%
-0.37
Net PPE Purchase And Sale
-0.19
+12.78%
-0.21
+64.03%
-0.60
0.00
Purchase Of PPE
-0.19
+12.78%
-0.21
+64.03%
-0.60
0.00
Capital Expenditure
-0.42
-3.74%
-0.40
+49.11%
-0.79
-943.01%
-0.08
Net Business Purchase And Sale
—
—
0.00
-100.00%
0.14
Purchase Of Business
—
—
—
0.00
Net Intangibles Purchase And Sale
-0.23
-22.47%
-0.19
+3.98%
-0.20
-159.05%
-0.08
Purchase Of Intangibles
-0.23
-22.47%
-0.19
+3.98%
-0.20
-159.05%
-0.08
Net Other Investing Changes
—
—
-0.02
+95.07%
-0.43
Financing Cash Flow
3.43
-71.28%
11.94
+228.74%
3.63
-59.92%
9.06
Cash Flow From Continuing Financing Activities
3.43
-71.28%
11.94
+228.74%
3.63
-59.92%
9.06
Net Issuance Payments Of Debt
—
0.00
-100.00%
4.50
0.00
Issuance Of Debt
—
0.00
-100.00%
4.50
0.00
Long Term Debt Issuance
—
0.00
-100.00%
4.50
0.00
Net Long Term Debt Issuance
—
0.00
-100.00%
4.50
0.00
Net Common Stock Issuance
3.80
-69.31%
12.39
0.00
-100.00%
11.99
Proceeds From Stock Option Exercised
—
0.00
-100.00%
0.39
0.00
Net Other Financing Charges
-0.37
+16.97%
-0.45
+64.16%
-1.26
+56.97%
-2.92
Changes In Cash
-2.72
-141.52%
6.54
+330.91%
-2.83
-178.62%
3.60
Beginning Cash Position
7.83
+509.84%
1.28
-68.83%
4.12
+703.00%
0.51
End Cash Position
5.11
-34.71%
7.83
+509.84%
1.28
-68.83%
4.12
Free Cash Flow
-6.15
-13.87%
-5.40
+16.53%
-6.47
-25.15%
-5.17
Interest Paid Supplemental Data
0.01
-20.60%
0.02
-38.87%
0.03
+423.09%
0.01
Income Tax Paid Supplemental Data
0.00
0.00
0.00
—
Common Stock Issuance
3.80
-69.31%
12.39
0.00
-100.00%
11.99
Issuance Of Capital Stock
3.80
-69.31%
12.39
0.00
-100.00%
11.99
Sale Of Business
—
—
0.00
-100.00%
0.14
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category